CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN)
today announced that Peter N. Kellogg has been appointed Executive Vice
President, Finance and Chief Financial Officer. Mr. Kellogg reports to James
C. Mullen, President and Chief Executive Officer.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Mr. Kellogg joined Biogen in July 2000 as Vice President, Finance and
Chief Financial Officer. From 1987-2000, he was associated with PepsiCo Inc.
in a variety of senior financial and management capacities in both Frito-Lay
International and PepsiCo. He was most recently Senior Vice President, PepsiCo
E-Commerce and Senior Vice President and Chief Financial Officer, Frito-Lay
International. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant
with Booz Allen & Hamilton and Arthur Andersen & Co.
In his position as Executive Vice President, Finance and Chief Financial
Officer, Mr. Kellogg will lead the Global Accounting, Business Planning, Tax,
Treasury, Investor Relations, and Strategic Sourcing functions.
Mr. Mullen said, "Peter Kellogg has made considerable contributions to
Biogen since joining the company a year ago. He has helped us refine Biogen's
corporate direction and demonstrated excellent leadership across the
organization. He plays a key strategic role on our senior management team and
contributes insights and experience to our challenge of building Biogen into a
global industry leader. He is also a superior manager and has added depth and
sophistication to our expanding worldwide finance functions."
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company's revenues are generated from international sales
of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products.
Biogen's research and development activities are focused on novel products to
treat inflammatory and autoimmune diseases, neurological diseases, cancer,
fibrosis and congestive heart failure. The Company maintains active clinical
research programs in protein therapeutics, small molecules, genomics and gene
therapy. For copies of press releases and additional information about the
Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com.
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com.
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/101550.html
CONTACT:
Media Contact: Kathryn R. Bloom, Senior
Director, Public Affairs, +1-617-679-2851, or Investment
Community Contact: Elizabeth Woo, Associate Director, Investor
Relations, +1-617-679-2822, both of Biogen, Inc.
|
